Innovation
We are advancing our internal pipeline to translate scientific ideas into future therapies. Our programs target oncology and other high-impact disease areas where unmet needs are still significant. By pursuing novel mechanisms, leveraging emerging technologies, and designing differentiated therapeutic strategies, we aim to create assets that are both scientifically rigorous and clinically meaningful. This balance of external partnerships and internal innovation positions Abhinavayan to contribute to the next generation of transformative therapies.
Our innovation priorities
​
The innovation at Abhinavayan is founded upon the promise it makes: to offer considerable alternatives to patients suffering from hard-to-treat cancer forms and rare diseases, for whom there are few or no options. The pipeline is developed along three core focuses, which form the backbone of a high-impact pipeline.
​
Transformative Oncology assets
The primary focus of Abhinavayan is on cancer therapies that could radically shift the course of the natural history of aggressive, refractory, or metastatic diseases rather than provide incremental benefits. These assets will help resist mechanisms, improve survival, and maintain the quality of life for the patient who has failed the current standard of care.​
​
-
Focus on high‑risk solid cancers and selected hematologic malignancies that experience inadequate outcomes despite treatment with more than one option.​​​​​​​​​​​​​​​​​​​​​​
-
The use of biomarkers and rational combinations from the start, such that every program can be developed with the specificity for patient selection in mind.
High‑impact rare and orphan indications
The focus of Abhinavayan is on rare and ultra-rare diseases, specifically rare cancers, where there is a strong biological imperative, but investment and development have been trailing behind the demand from patients. These diseases are faced with challenges of late diagnosis, unmet therapeutics, and poor commercial reward, among others.​
​
-
Focusing on molecularly defined diseases that are amenable to targeting or specialty approaches and allow for first‑or best‑in‑class opportunities.​
-
Development strategies that rely upon orphan and accelerated regulatory procedures, in conjunction with evidence strategies that facilitate sustainable access to small and geographically dispersed patient populations.​
Translational and biomarker innovation
Abhinavayan believes that the area of translational science and biomarkers can be considered a common platform that drives every single program. Every new asset that is developed builds upon the benefits of the existing ones.
​
-
In vitro, in vivo, and data science expertise that is highly developed and readily applicable across the oncology and rare disease pipelines to inform hypotheses related to biology, indication, and patient care.​
-
Systematic gathering of learnings from clinical and real-world experiences to progressively improve the engine in each iteration from early signal to go/no-go.
